ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

439
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
bullishWuxi Biologics
23 Sep 2022 11:21

Shanghai/​​​​​​​​​​​​​Shenzhen Southbound Connect: Weekly Moves (23 September 2022)

Inside is a recap of movements in the Shanghai/Shenzhen-HK Connect. Overall, the net inflow over the past week was ~US$1.1bn, split (-US$0.8bn) for...

Logo
280 Views
Share
23 Sep 2022 10:19

Hong Kong Buybacks Weekly (Sep 23rd): Buyback at One Year High

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
264 Views
Share
19 Sep 2022 08:46

About the CXO Plunge After Biden Signed National Biotechnology and Biomanufacturing Initiative

CXO plunged after Biden signed the National Biotechnology and Biomanufacturing Initiative. As tensions between China and US escalate, it is no...

Logo
271 Views
Share
17 Sep 2022 15:56

Hong Kong Connect Flows (Sep 16th): Chinese Buying Wuxi Biologics After Biden's New Executive Order

We analyzed Hong Connect flows last week and highlight Chinese purchase of Wuxi Biologics post new executive order signed on Monday.

Logo
358 Views
Share
16 Sep 2022 10:57

Hong Kong Buybacks Weekly (Sep 16th): Tencent, AIA, Xiaomi, Swire, Fosun Intl

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
299 Views
Share
x